Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
Benedikt HoehChristoph WürnschimmelRocco Simone FlammiaBenedikt HorlemannGabriele SorceFrancesco ChierigoZhe TianFred SaadMarkus GraefenMichele GallucciAlberto BrigantiCarlo TerroneShahrokh F ShariatDerya TilkiLuis A KluthPhilipp MandelFelix K H ChunPierre I KarakiewiczPublished in: The Prostate (2022)
Caucasian and Asian de novo metastatic prostate cancer patients exhibit the greatest overall survival benefit from chemotherapy exposure. Conversely, no overall survival benefit from chemotherapy exposure could be identified in either African-Americans or Hispanic/Latinos. Further studies are clearly needed to address these race/ethnicity specific disparities.